# PK Study on Ready-to-Use Injection (VSLI-RTU) 1 Vial & 3 Vial Formulation Marqibo® in Hematological Malignant Patients

> **NCT04243434** · PHASE1 · UNKNOWN · sponsor: **Acrotech Biopharma Inc.** · enrollment: 56 (estimated)

## Conditions studied

- Hematologic Diseases

## Interventions

- **DRUG:** Vincristine Sulfate Liposome
- **COMBINATION_PRODUCT:** CHOP
- **COMBINATION_PRODUCT:** R-CHOP

## Key facts

- **NCT ID:** NCT04243434
- **Lead sponsor:** Acrotech Biopharma Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-08-15
- **Primary completion:** 2020-08-15
- **Final completion:** 2020-10-15
- **Target enrollment:** 56 (ESTIMATED)
- **Last updated:** 2020-04-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04243434

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04243434, "PK Study on Ready-to-Use Injection (VSLI-RTU) 1 Vial & 3 Vial Formulation Marqibo® in Hematological Malignant Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04243434. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*